ESR2 and prostate carcinoma: Two proteins-hsa:2099 (Estrogen receptor) and hsa:2100 (Estrogen receptor beta), both of which play crucial roles in many cancer types such as breast cancer [22] and prostate cancer [23].-are considered to be the most possible targets (rank 1 and rank 2, respectively) for the drug.